ValiRx (LSE:VAL) ROE % Adjusted to Book Value : -71.23% (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx ROE % Adjusted to Book Value?

ValiRx's ROE % for the quarter that ended in Dec. 2024 was -46.30%. ValiRx's PB Ratio for the quarter that ended in Dec. 2024 was 0.65. ValiRx's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -71.23%.

ValiRx ROE % Adjusted to Book Value Historical Data

The historical data trend for ValiRx's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx ROE % Adjusted to Book Value Chart

ValiRx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.46

-5.41

-19.89

-29.51

-78.23

ValiRx Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-25.54	-28.33	-28.42	-50.42	-71.23

Competitive Comparison of ValiRx's ROE % Adjusted to Book Value

For the Biotechnology subindustry, ValiRx's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ValiRx's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

ValiRx ROE % Adjusted to Book Value Calculation

ValiRx's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-50.85%	/	0.65
	=	-78.23%

ValiRx's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-46.30%	/	0.65
	=	-71.23%

ValiRx ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ValiRx's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.